Great news for our "Wet" Age Related Macular Degeneration patients on current anti-VEGF therapy. Regeneron is awaiting an FDA decision by November 18, 2011 for EYLEA. Eylea requires less doses than the current treatment Lucentis, and in clinical studies achieves the same results. Patients will receive Eylea every eight weeks after an initial monthly dose for the first three months. Currently, Lucentis is administered every four weeks. South Texas Retina is ready to get immediate shipment on release. Click here for the company release.